REFERENCES
  1. Wallentin L, Becker RC, Budaj, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 61:1045-1057
  2. Serebruany VL. Paradoxical excess mortality in the PLATO trial should be independently verified.Thromb Haemost 2011;105:752-759.
  3. The FDA ticagrelor review of complete response. Available for download at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000MedR.pdf Assessed June 15, 2020
  4. Neumann F-J, Sousa-Uva M, Ahlsson A, et al. ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87–165
  5. Mehta SR, Bainey KR, Cantor WJ, et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy.Can J Cardiol 2018;34:214-233
  6. Levine GN, Bates ER, Bittle JA. et al. ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. JACC; 2016; 68:1082–1115
  7. Serebruany V, Tanguay J-F, Benavides MA, et al. Verifying Death Reports in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.Amer J Therap 2020; 27:e563-e572
  8. DiNicolantonio JJ, Tomek A. Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. Int J Cardiol 2013;169:145-146
  9. Varenhorst C, Alström U, Braun OO, et al. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart 2014;100:1762-1769
  10. Storey RF, James SK, Siegbahn A, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets 2014;25:517-525
Table. Primary deaths causes in the FDA- and PLATO Investigators datasets